Sphingosine 1-phosphate receptor modulators in multiple sclerosis - Wikidata - awgldk - TriplyDB

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

http://www.wikidata.org/entity/Q26799440

about

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.Expression profiling of genes regulated by sphingosine kinase1 signaling in a murine model of hyperoxia induced neonatal bronchopulmonary dysplasia Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Safety concerns and risk management of multiple sclerosis therapies.Can new chemical therapies improve the management of multiple sclerosis in children?Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.

P2860

Q26765300-10F1374D-8746-4BE3-9DA2-8FE6C87BEEE0 Q26771821-ED741A41-D842-4310-BA2A-288550636DE5 Q35933419-7A167C1A-0C0C-4767-BDE1-CBFA72972666 Q36986113-3D8B56C5-1C40-4CEB-BC02-F9A136871217 Q37551932-BC7589DF-054B-4956-AD0F-3566CF92F784 Q38603475-77822499-20C3-43AA-B7D4-C817859556EC Q38622668-B2DA3F21-BEAE-4BB8-A9D8-3445502CC579 Q38816194-BCDB79FA-9868-4547-9EF5-0D99ED80DB14 Q38837294-BA540279-898E-48DC-B3E5-DE632FB9B3FE Q39021781-C9FD0219-1F2F-435A-96C1-E7A7B53BC1BD Q39024427-FF8F7AE8-1169-4DC5-B68C-C34F32983D9E Q39448667-9A74C6A6-A582-4854-A593-7ACA8F2A7C85 Q40047199-9F78F50D-F89C-4364-951F-2F81D973198A Q40786516-2F55B295-45A1-4EAE-9CB8-66EA52C1FF7B Q41052913-8D655D37-FC4E-4F30-B288-A597A3FB420D Q47155392-028EEC6E-CCDA-426E-80DC-5C1B04AA1CBD Q49164654-53EB16E5-4C01-42F8-8FEE-87766B373F45 Q50070747-05483225-A65F-4846-BC08-FE60AB8D4297 Q50624974-218ED5E6-425D-4886-9869-4E3CC75458E1 Q54736314-23204B4D-5256-45E2-81AF-6007C04A249D

P2860

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

http://www.wikidata.org/entity/Q26799440

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@ast

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@en

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@nl

type

label

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@ast

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@en

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@nl

prefLabel

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@ast

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@en

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@nl

P1433

Q26799440-46B22803-9F5C-4E2C-A36B-477204E2D05E

P1476

Q26799440-E287DF73-FB54-419E-AED9-9FEDC02B72C3

P2093

Q26799440-1FF0AC7A-597B-4258-837B-8B997A9E0F90

Q26799440-606ABAA6-570E-4401-8305-1275D8E3C965

P2860

Q26799440-0212BEDD-A133-40D5-A6C6-2373FDF49D47

Q26799440-0C32F2FB-3F55-41EC-AE91-C084853F7F39

Q26799440-0F366FA8-DE0E-4CC0-B127-E670BFA36AB0

Q26799440-1732F446-2344-4DC4-A138-0B84618BFACE

Q26799440-1B3F4F83-C3DE-4026-9FDF-DEF93D5E7703

Q26799440-22E402BB-54ED-4DB0-8279-AFD63D716FC0

Q26799440-2D56F9B6-3D87-459C-8B55-41F96B83DCB2

Q26799440-46620650-7580-4FA3-A113-B5079F82222D

Q26799440-52CDD7F1-2059-45E8-AC32-4DFB03982EE4

Q26799440-54972507-EA51-44F6-9D2F-48AA2F0D02FF

P2888

Q26799440-7C961D9E-948F-4304-88D6-7AC300D2E853

P304

Q26799440-47D10E38-FFAB-4CD0-BDA3-9190ECEE2F7D

P31

Q26799440-45712AD7-352D-432E-83E8-4B39520CEF38

P3181

Q26799440-7F7D3665-08D2-4061-9BB7-6FB30ACF262D

P356

Q26799440-AA6975A5-D788-49C6-92E5-9AEEB344AF4F

P407

Q26799440-51E4E696-201B-4651-A9AC-80CA5EE24405

P433

Q26799440-BC95D8CB-6E6A-4B76-93B6-82A59A1B0636

P478

Q26799440-1671A4F4-A4C5-4069-8C2A-D048EB2D3CBC

P577

Q26799440-D6816534-A8CB-496E-950D-7291E00360E2

P6179

Q26799440-7E210438-F20D-42A4-A851-C577E8E5EECD

P698

Q26799440-F93FCCDE-65BB-43B5-9E52-70DD8F028268

P921

Q26799440-D4219547-C9F5-4BDA-8F0E-F72E792D191F

P932

Q26799440-5594E0A8-8907-4125-A419-8440085BC872

P3181

P356

S40263-015-0261-Z

P1433

P1476

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

@en

P2093

Adnan M Subei

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Cohen

http://www.w3.org/2001/XMLSchema#string

P2860

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

P2888

s40263-015-0261-z

P304

565-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

914362

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40263-015-0261-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021358377

http://www.w3.org/2001/XMLSchema#string

P698

26239599

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4554772

http://www.w3.org/2001/XMLSchema#string